Skip to main content

Blocking integrin ?1 decreases adhesion in chemoresistant urothelial cancer cell lines

Vallo, Stefan, Rutz, Jochen, Kautsch, Miriam, Winkelmann, Ria, Michaelis, Martin, Wezel, Felix, Bartsch, Georg, Haferkamp, Axel, Rothweiler, Florian, Blaheta, Roman A, and others. (2017) Blocking integrin ?1 decreases adhesion in chemoresistant urothelial cancer cell lines. Oncology letters, 14 (5). pp. 5513-5518. ISSN 1792-1074. (doi:10.3892/ol.2017.6883) (KAR id:66959)

Abstract

Treatment failure in metastatic bladder cancer is commonly caused by acquisition of resistance to chemotherapy in association with tumor progression. Since alterations of integrins can influence the adhesive and invasive behaviors of urothelial bladder cancer cell lines, the present study aimed to evaluate the role of integrins in bladder cancer cells with acquired resistance to standard first-line chemotherapy with gemcitabine, and cisplatin. Therefore, four gemcitabine- and four cisplatin-resistant sublines out of a panel of four parental urothelial bladder cancer cell lines (TCC-SUP, HT1376, T24, and 5637) were used. Expression of integrin subunits ?3, ?5, ?6, ?1, ?3, and ?4 was detected using flow cytometry. Adhesion and chemotaxis were analyzed. For functional assays, integrin ?1 was attenuated with a blocking antibody. In untreated cells, chemotaxis was upregulated in 3/4 gemcitabine-resistant sublines. In cisplatin-resistant cells, chemotaxis was enhanced in 2/4 cell lines. Acquired chemoresistance induced the upregulation of integrin ?1 in all four tested gemcitabine-resistant sublines, as well as an upregulation in 3/4 cisplatin-resistant sublines compared with parental cell lines. Following the inhibition of integrin ?1, adhesion to extracellular matrix components was downregulated in 3/4 gemcitabine-resistant sublines and in all four tested cisplatin-resistant sublines. Since integrin ?1 is frequently upregulated in chemoresistant urothelial cancer cell lines and inhibition of integrin ?1 may influence adhesion, further studies are warranted to evaluate integrin ?1 as a potential therapeutic target for bladder cancer.

Item Type: Article
DOI/Identification number: 10.3892/ol.2017.6883
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Divisions > Division of Natural Sciences > Biosciences
Depositing User: Martin Michaelis
Date Deposited: 09 May 2018 10:43 UTC
Last Modified: 04 Mar 2024 17:44 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/66959 (The current URI for this page, for reference purposes)

University of Kent Author Information

  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.